Fundraising Fox
🦊/People
Sign in

Chad May

CSO at Orum Therapeutics Venture Capital

San Carlos, California, United States

Find your path to Chad

168 people in our graph share verified history with Chad — schools, employers, funds. One of them is your warm intro.

David KaufmanunlockedChad: together at Joan & Sanford I. Weill Medical College of Cornell University (1995–2001)
×2Chad: together at Maverick Therapeutics
×2Chad: together at University of Minnesota
×3Chad: together at Joan & Sanford I. Weill Medical College of Cornell University

About

Chad May is Chief Scientific Officer at Orum Therapeutics, where he leads scientific research and development and preclinical oncology research from target validation and candidate selection through IND submission and Phase 1 clinical trials. His work covers therapeutic modalities including monoclonal antibodies, antibody drug conjugates, radioconjugates, T cell engagers, and CAR-T cell therapies, along with portfolio strategy, business development, and investor relations.

CSO at Orum Therapeutics Venture Capital

Intro paths

→

In turn, Chad can intro founders to Orum Therapeutics Venture Capital's investors below.

Orum Therapeutics Venture Capital's investors · 5

Atinum Investment Co. Ltd.Seoul · $100K – $2M checksIMM Investment JapanSeoulLB InvestmentSeoulSolidus InvestmentSeoulXquared VCSeoul

Co-founders at Orum Therapeutics Venture Capital

SLSJ Lee
SJ LeeCEO

Experience

  1. Orum TherapeuticsChief Scientific Officercurrent2025 — presentLexington, Massachusetts, United States
  2. Johnson & Johnson Innovative MedicineHead of Serotiny, Therapeutics Design & Development2024South San Francisco, California, United States
  3. SerotinyChief Scientific Officer2022 — 2024South San Francisco, California, United States
  4. Maverick TherapeuticsSenior Vice President Research And Development2017 — 2022Brisbane, CA
  5. Pfizer PharmaceuticalsSenior Director, Targeted Immunotherapy2010 — 2017Pearl River, NY
  6. ImClone SystemsSenior Scientist2001 — 2010
  7. Memorial Sloan-Kettering Cancer CenterPost Doctoral Fellow2001
  8. University of Minnesota-Twin CitiesResearch Associate1993 — 1995

Skills & more

Portfolio StrategyFundraisingInvestor RelationsBusiness DevelopmentC Level ManagementBiotechnology14Immunology11Drug Discovery23Molecular Biology16Drug Development12Assay Development16ELISA3
+9 moreOncologyLifesciencesCell CultureIn VivoCellProtein ChemistryMonoclonal AntibodiesCell BiologyCompany Vision

From Chad's professional profile.

Frequently asked questions

Who is Chad May?
Chad May is Chief Scientific Officer at Orum Therapeutics, where he leads scientific research and development and preclinical oncology research from target validation and candidate selection through IND submission and Phase 1 clinical trials. His work covers therapeutic modalities including monoclonal antibodies, antibody drug conjugates, radioconjugates, T cell engagers, and CAR-T cell therapies, along with portfolio strategy, business development, and investor relations.
Where does Chad May work?
Chad May is CSO at Orum Therapeutics Venture Capital.
Where did Chad May go to school?
Chad May studied at Joan & Sanford I. Weill Medical College of Cornell University (PhD, Immunolgy); University of Minnesota (B.S., Genetics and Cell Biology).

Same school

Shared employers